## DESCRIPTION

**Source**
Mouse myeloma cell line, NS0-derived  
Met1-Glu480  
Accession # CAA30051

**N-terminal Sequence Analysis**
Not obtained, Predicted Gln28

**Predicted Molecular Mass**
50 kDa

## SPECIFICATIONS

**SDS-PAGE**
70-90 kDa, reducing conditions

**Activity**
Measured by the ability of the immobilized protein to support the adhesion of PMA-stimulated HSB2 human peripheral blood acute lymphoblastic leukemia cells.  
When 5 x 10^4 cells/well are added to Recombinant Human ICAM-1/CD54 coated plates (12.5 μg/mL with 100 μL/well), >30% cells will adhere after 1 hour incubation at 37 °C.  
Optimal dilutions should be determined by each laboratory for each application.

**Endotoxin Level**
<0.10 EU per 1 μg of the protein by the LAL method.

**Purity**
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

**Formulation**
Lyophilized from a 0.2 μm filtered solution in PBS, containing Calcium and Magnesium with Sorbitol and with Trehalose. See Certificate of Analysis for details.

## PREPARATION AND STORAGE

**Reconstitution**
Reconstitute at 400 μg/mL in sterile PBS.

**Shipping**
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage**
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.  
- 12 months from date of receipt, -20 to -70 °C as supplied.  
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.  
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

## BACKGROUND

Interleukin-1 (ICAM-1) binds the leukocyte integrins LFA-1 and Mac-1. ICAM-1 expression is weak on leukocytes, epithelial and resting endothelial cells, as well as some other cell types, but expression can be stimulated by IFN-γ, TNF-α, IL-1β and LPS. Soluble ICAM-1 is found in a biologically active form in serum, probably as a result of proteolytic cleavage from the cell surface, and is elevated in patients with various inflammatory syndromes such as septic shock, LAD, cancer and transplantation.